Literature DB >> 7722302

Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow.

O W Rokhlin1, M B Cohen, H Kubagawa, M Letarte, M D Cooper.   

Abstract

Endoglin, a glycoprotein that is expressed by human endothelial cells, binds TGF-beta 1 and -beta 3 with high affinity. It was originally identified with the 44G4 mAb that was produced against a human pre-B cell line. We now report that another anti-pre-B cell mAb, 29-G8, reacts with pro-B and pre-B leukemic cells, but not with mature B and T cells, and recognizes a different epitope of endoglin. The 29-G8 mAb bound specifically to recombinant endoglin and immunoprecipitated a phosphorylated homodimeric glycoprotein with subunits of M(r) 95,000 from the 697 pre-B cell line. This new Ab removed all of the molecules identified by the prototypic 44G4 anti-endoglin Ab, but the reverse was not true. A subpopulation of 29-G8+ endoglin molecules on this pre-B cell line was unreactive with the 44G4 mAb, thus suggesting that these anti-endoglin Abs see different epitopes that may discriminate different species of endoglin molecules. Flow cytometric analysis with the 29-G8 mAb revealed two endoglin-positive subpopulations in fetal bone marrow: early B-lineage precursor cells (CD19+ and CD34+), and proerythroblasts (CD71+ and glycophorin A+). In adult bone marrow, only the proerythroblast subpopulation was observed. Stromal cells derived from fetal bone marrow also reacted strongly with the 29-G8 and 44G4 Abs, and these cells responded with enhanced proliferation after stimulation with either TGF-beta 1 or the anti-endoglin Abs. Thus, endoglin, a specialized component of the TGF-beta receptor system, may play a physiologic role in the stromal-hemopoietic cell interactions occurring during development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7722302

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Prospective isolation of human erythroid lineage-committed progenitors.

Authors:  Yasuo Mori; James Y Chen; John V Pluvinage; Jun Seita; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-20       Impact factor: 11.205

Review 2.  Endoglin for targeted cancer treatment.

Authors:  Lee S Rosen; Michael S Gordon; Francisco Robert; Daniela E Matei
Journal:  Curr Oncol Rep       Date:  2014-02       Impact factor: 5.075

3.  Expression of normal and truncated forms of human endoglin.

Authors:  U Raab; B Velasco; P Lastres; A Letamendía; C Calés; C Langa; E Tapia; J P López-Bote; E Páez; C Bernabéu
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

4.  Runx1 and Cbfβ regulate the development of Flt3+ dendritic cell progenitors and restrict myeloproliferative disorder.

Authors:  Ansuman T Satpathy; Carlos G Briseño; Xiongwei Cai; Drew G Michael; Chun Chou; Sunnie Hsiung; Deepta Bhattacharya; Nancy A Speck; Takeshi Egawa
Journal:  Blood       Date:  2014-03-27       Impact factor: 22.113

5.  A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.

Authors:  Lee S Rosen; Herbert I Hurwitz; Michael K Wong; Jonathan Goldman; David S Mendelson; William D Figg; Shawn Spencer; Bonne J Adams; Delia Alvarez; Ben K Seon; Charles P Theuer; Bryan R Leigh; Michael S Gordon
Journal:  Clin Cancer Res       Date:  2012-07-05       Impact factor: 12.531

6.  Expression levels of endoglin distinctively identify hematopoietic and endothelial progeny at different stages of yolk sac hematopoiesis.

Authors:  Luciene Borges; Michelina Iacovino; Naoko Koyano-Nakagawa; June Baik; Daniel J Garry; Michael Kyba; Rita C R Perlingeiro
Journal:  Stem Cells       Date:  2013-09       Impact factor: 6.277

7.  A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.

Authors:  Roberto Romero; Jyh Kae Nien; Jimmy Espinoza; David Todem; Wenjiang Fu; Hwan Chung; Juan Pedro Kusanovic; Francesca Gotsch; Offer Erez; Shali Mazaki-Tovi; Ricardo Gomez; Sam Edwin; Tinnakorn Chaiworapongsa; Richard J Levine; S Ananth Karumanchi
Journal:  J Matern Fetal Neonatal Med       Date:  2008-01

8.  Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin.

Authors:  Guang-Hong Tan; Feng-Ying Huang; Hua Wang; Yong-Hao Huang; Ying-Ying Lin; Yue-Nan Li
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

9.  Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis.

Authors:  Hongxia Yan; Abdullah Ali; Lionel Blanc; Anupama Narla; Joseph M Lane; Erjing Gao; Julien Papoin; John Hale; Christopher D Hillyer; Naomi Taylor; Patrick G Gallagher; Azra Raza; Sandrina Kinet; Narla Mohandas
Journal:  Am J Hematol       Date:  2021-06-03       Impact factor: 13.265

10.  Molecular pathways of early CD105-positive erythroid cells as compared with CD34-positive common precursor cells by flow cytometric cell-sorting and gene expression profiling.

Authors:  S Machherndl-Spandl; S Suessner; M Danzer; J Proell; C Gabriel; J Lauf; R Sylie; H-U Klein; M C Béné; A Weltermann; P Bettelheim
Journal:  Blood Cancer J       Date:  2013-01-11       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.